Related Experiment Video
Updated: Jan 6, 2026
Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
Published on: May 29, 2020
A Pharmacovigilance Study of Immune Checkpoint Inhibitor-Associated Cholangitis: Insights From the FDA Adverse Event
Haowen Tan1,2, Xuan Ou1, Ying Chen1
1Office of Good Clinical Practice, Wuzhou Red Cross Hospital, Wuzhou, China.
Aim:
Immune checkpoint inhibitor (ICI)-associated cholangitis is a rare immune-related adverse event (irAE). However, large-scale clinical studies specifically investigating this toxicity are still lacking. The aim was to describe ICI-associated cholangitis reported to the United States Food and Drug Administration Adverse Event Reporting System (FAERS).
Methods:
Reports of irAEs were extracted from the FAERS database (Q1 2011 to Q4 2024). Cases of ICI-associated cholangitis were identified using the following Preferred Terms from the Medical Dictionary for Regulatory Activities (version 27.1): "cholangitis," "sclerosing cholangitis," and "immune-mediated cholangitis". Reporting odds ratio (ROR) method was performed to evaluate the association between cholangitis and different ICI therapies. Additionally, the clinical features of ICI-associated cholangitis were characterized, and the time-to-onset (TTO) of cholangitis following ICI treatment was assessed.
Results:
A total of 1102 patients with ICI-associated cholangitis were identified. Male patients (n = 628, 56.99%) outnumbered females (n = 334, 30.31%). Most patients were aged ≥ 65 years (n = 540, 49.00%). Hospitalization (n = 454, 41.20%) was the most frequent clinical outcome. Programmed cell death protein 1 inhibitors showed the strongest risk association (ROR = 24.65 and 95% confidence interval [CI]: 22.84-26.59), followed by programmed death-ligand 1 inhibitors (ROR = 19.03 and 95% CI: 16.41-22.08). In contrast, cytotoxic T-lymphocyte-associated protein 4 inhibitors showed no significant association (ROR = 2.08 and 95% CI: 0.93-4.64). The median TTO was 77 days (interquartile range: 31-164 days).
Conclusion:
From a pharmacovigilance perspective, this study characterizes certain clinical features of ICI-associated cholangitis, elucidates distinct risk profiles across ICI classes, and emphasized the importance of constant monitoring. However, further studies remain essential to fully understand this rare irAE.
More Related Videos
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
06:07Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
